Trial Profile
Residual Neuromuscular Blockade in Cardiac Surgery Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/neostigmine (Primary) ; Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 01 Feb 2022 Planned End Date changed from 30 Mar 2019 to 30 Aug 2018.
- 01 Feb 2022 Planned primary completion date changed from 30 Dec 2018 to 30 Aug 2018.
- 01 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment due to inadequate funding.